Radiopharm Theranostics (ASX:RAD) and AtomVie Global Radiopharma partnered with Radiopharm Ventures to develop and manufacture the 177Lu-BetaBart radio-antibody for treating solid tumors, according to a Wednesday filing with the Australian Securities Exchange.
The first-in-human therapeutic trial with 177Lu-BetaBart is set to start in the US in 2025, the filing said.
Radiopharm Ventures is a joint venture between Radiopharm Theranostics and MD Anderson Cancer Center in Texas, according to the filing.
Shares of Radiopharm Theranostics rose nearly 4% in midday trade.
Price (AUD): $0.03, Change: $+0.0010, Percent Change: +3.85%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。